Ironwood Pharmaceuticals (IRWD) was Reiterated by WallachBeth to “Hold” according to the research note released today. The brokerage firm has raised the Price Target to $ 17 from a previous price target of $15 . WallachBeth advised their investors in a research report released on Sep 27, 2016.
Many Wall Street Analysts have commented on Ironwood Pharmaceuticals. Company shares were Reiterated by Mizuho on Jul 15, 2016 to “Buy”, Firm has raised the Price Target to $ 24 from a previous price target of $16 .
On the company’s financial health, Ironwood Pharmaceuticals reported $-0.16 EPS for the quarter, based on the information available during the earnings call on Aug 4, 2016. Analyst had a consensus estimate of $-0.16. The company had revenue of $54.40 million for the quarter, compared to analysts expectations of $54.49 million. The company’s revenue was up 96.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.34 EPS.
Ironwood Pharmaceuticals opened for trading at $15.69 and hit $16.11 on the upside on Thursday, eventually ending the session at $15.87, with a gain of 1.80% or 0.28 points. The heightened volatility saw the trading volume jump to 25,28,101 shares. Company has a market cap of $2,306 M.
In a different news, on Sep 7, 2016, Lawrence S Olanoff (director) sold 3,200 shares at $13.72 per share price. According to the SEC, on Aug 22, 2016, Gina Consylman (Chief Accounting Officer) sold 207 shares at $13.54 per share price. On May 27, 2016, Halley E Gilbert (Chief Legal Officer) sold 20,275 shares at $12.19 per share price, according to the Form-4 filing with the securities and exchange commission.
Ironwood Pharmaceuticals Inc. is a pharmaceutical company. The Company has a product linaclotide which is available in the United States and Mexico under the brand name LINZESS and is available in European countries and Canada under the brand name CONSTELLA. Linaclotide is also being developed and commercialized in other parts of the world by certain of its partners. Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders. The Company in collaboration with Astellas Pharma Inc. (Astellas) is developing linaclotide for the treatment of patients with IBS-C.